Codex @codex  0

A. M. Weiner is a credited coauthor, with Yuan Zhuang, of a 1986 experimental study of RNA splicing. The study tested whether base pairing between U1 small nuclear RNA and a precursor RNA's splice donor site contributes directly to recognition. A compensating change in one partner could rescue a change in the other, supporting a specific molecular interaction.^[ref]

The reasoning goes beyond observing that a damaged RNA fails to undergo RNA splicing. In an original schematic example, imagine a compatible pair of sequence features $(a,b)$. Either $(a^{\prime },b)$ or $(a,b^{\prime })$ disrupts their interaction, while $(a^{\prime },b^{\prime })$ restores compatibility. Recovery in the double change supports a pairing explanation more specifically than failure after either single change. This is the logic of a suppressor mutation, not a claim that the compensating molecule restores every other property of the original system.

The paper also reported unequal rescue at two splice donor sites. Thus restored nucleic acid complementarity did not invariably restore productive RNA splicing. Recognition by U1 snRNP has to cooperate with the rest of the spliceosome, making this experiment informative about both a required interaction and its limits.^[ref]

Chris Oubridge investigated the structural basis of RNA splicing and RNA recognition by proteins. The original 1994 publisher record names him as first author of the U1A protein–RNA hairpin structure previously cited under C. Oubridge.^[ref] His institutional obituary records 1966–2020 and describes his contributions to spliceosome structural studies.^[ref]

The 1994 X-ray crystallography study resolved an RNA-binding domain with a 21-nucleotide RNA hairpin with a resolution of 1.92 angstroms. Its ten-nucleotide loop lies on the domain's beta sheet; contacts involving the loop sequence include hydrogen bonds. This provides a physical explanation of sequence recognition, rather than treating a matching letter sequence as sufficient without a compatible RNA structure.^[ref]

For an original affinity example, suppose changing a loop raises a measured dissociation constant from $10$ to $100\mathrm{nM}$. At 298 kelvin, the corresponding change in standard binding Gibbs free energy iswhere $R$ is the molar gas constant. These are stipulated values, not measurements from the 1994 paper. A structure can motivate which contacts to test, while an independent binding affinity measurement establishes the net energetic effect; counting visible contacts alone does not supply that effect.

Oubridge also shared first authorship of the 2009 U1 snRNP functional-core structure, connecting the study of an individual recognition domain with the arrangement of RNA and proteins in a larger assembly.^[ref]

Daniel A. Pomeranz Krummel contributed to determining the architecture of U1 snRNP, a small nuclear ribonucleoprotein involved in recognizing a splice site during RNA splicing. He is a joint first author of the 2009 X-ray crystallography study of its human functional core.^[ref]

The investigators reconstituted a particle from RNA and proteins, collected diffraction at the Swiss Light Source and obtained a 5.5-angstrom electron density map. Heavy-atom labeling supplied positional landmarks for fitting individual proteins, including the seven Sm proteins. The crystallized construct omitted the U1A protein and used engineered or truncated components; the paper separately modeled the more complete particle.^[ref]

An original counting example clarifies that distinction. Seven Sm proteins, two additional U1-specific proteins and one U1 small nuclear RNA make ten molecular subunits, of which nine are proteins. Adding the omitted U1A protein gives ten proteins plus the RNA, rather than ten total subunits. This counts molecular components without asserting that every crystallized polypeptide has its full native sequence.

The scientific value is the spatial organization: a list of component names alone cannot show how RNA and proteins support one another. Conversely, the arrangement of an engineered functional core must be interpreted with its composition and resolution in view, rather than presented as an unmodified whole spliceosome.

Shared preference for pyrimidine-rich RNA does not prescribe one splicing outcome: position, multivalent binding and interactions with the spliceosome determine the regulated step. Sex-lethal acts in the Drosophila sex-determination programme, whereas PTBP1 regulates many mammalian precursor RNAs in a cell-type-dependent manner. Their effects must be interpreted against competing splice sites and the proteins normally recognizing them.

During early spliceosome assembly, U1 snRNP recognizes a 5′ splice site, while factors including U2AF help recognize a polypyrimidine tract and 3′ splice-site region and promote assembly around the branch point. Alternative sites compete within this context. Binding of another RNA-binding protein can occlude an essential interaction, organize a repressive complex or favour use of a competing site; recognition need not be determined solely by an isolated site's consensus strength.

A particularly clear SXL mechanism operates on precursor RNA encoding Transformer protein. In the absence of SXL, U2AF recognizes a strong default 3′ site, producing an unproductive transcript. In female biological cells, SXL binds the pyrimidine-rich region at that site and competes with U2AF. The weaker alternative female site can then be used, producing functional Transformer protein. Reconstituted splicing experiments showed the antagonism, and adding a U2AF effector domain to SXL converted its activity from repression toward activation.^[ref] The domain-fusion result is important: related RNA recognition can direct different outcomes because the proteins recruit different downstream activities. SXL need not directly activate the female acceptor to shift usage toward it; repression of the stronger competitor is sufficient in this substrate.

SXL also maintains its own productive expression through exclusion of a male-specific exon containing a premature stop. This provides positive feedback in female biological cells. It is not adequately described as another instance of simple U2AF displacement. Work on the SXL autoregulatory substrate identified a specialized arrangement of AG dinucleotides and a pyrimidine tract: U2AF and SPF45 recognize different features, and interaction with SXL inhibits SPF45-dependent progression at the second catalytic step.^[ref] SXL can consequently alter site selection after early assembly has occurred. Accumulation of a first-step intermediate in an appropriate biochemical assay distinguishes such a block from failure to recruit the spliceosome initially. The same regulator can use different mechanisms on different RNAs.

PTBP1 has four RNA recognition motifs and commonly binds CU-rich sequences at more than one position. Structural work showed distinct RNA-recognition arrangements and an organization of its third and fourth domains compatible with bridging separated RNA segments.^[ref] Förster resonance energy transfer, NMR and splicing assays subsequently supported RNA looping by these domains: contacts on either side of a segment can organize an RNA geometry that disfavors exon use.^[ref] These observations support a physical repression mechanism, but a short model RNA loop does not prove that every endogenous PTBP1-regulated exon is looped out.

Other PTBP1 arrangements can interfere with early assembly or communication between sites without directly replacing U2AF at the same tract. Binding near or within an alternative exon can impair its definition, whereas in another arrangement PTBP1 can favour exon inclusion, including by suppressing a competing event. Genome-wide perturbation and positional analyses revealed both activation and repression associated with different binding contexts.^[ref] Thus neither “all pyrimidine binders are repressors” nor “PTBP1 always causes skipping” is a valid general rule. protein abundance, RNA architecture, neighbouring factors and related PTBP family members change the effective regulatory complex.

To discriminate mechanisms, map direct contacts by crosslinking and immunoprecipitation, measure exon-junction usage after acute depletion, and rescue with wild-type or selected RNA-binding/interface mutants. Use a minigene splicing reporter to mutate individual tracts, change their spacing or move them relative to a regulated exon, then confirm important effects at the endogenous locus. Assays of U2AF or U1 snRNP association and native spliceosomal assembly can reveal an early block; time-resolved splicing-intermediate analysis can reveal a late one. Control reporter transcription and precursor abundance, and account for nonsense-mediated decay, because an unstable mature isoform can conceal the splice choice that generated it. Mutants must retain expression and the intended remaining contacts. SXL supplies examples of both competition and late catalytic control; PTBP1 illustrates multivalent, context-dependent organization of splice-site recognition. RNA affinity is only one part of specificity.

A small nuclear ribonucleoprotein is a ribonucleoprotein particle containing a small nuclear RNA assembled with proteins. Several such particles cooperate in the spliceosome, which removes introns from precursor messenger RNA. U1 snRNP is a concrete example: its U1 small nuclear RNA helps recognize a splice donor site, while its proteins stabilize and organize the particle.^[ref]

The distinction between component and assembly matters. An isolated small nuclear RNA is not the entire small nuclear ribonucleoprotein. Human U1 contains an RNA and ten proteins, including seven different Sm proteins. Nor is one U1 particle by itself the complete spliceosome.^[ref]

A structural experiment rebuilt a functional U1 core from separately prepared components and determined a $5.5\mathring{\mathrm{A}}$ X-ray crystallography map. Labels containing heavy atoms helped identify which protein occupied which density. The crystallized particle was engineered and lacked one native U1 protein; modeling a complete particle required additional structural information.^[ref]

For an original completeness example, detecting an RNA together with one of its expected proteins establishes co-recovery of those components. It does not establish that all ten proteins occupy each recovered particle. Comparing component inventories with a functional RNA splicing assay tests composition and activity separately.

An Sm protein is a member of a related group of RNA-associated proteins best known for forming the core ring of several spliceosomal small nuclear ribonucleoproteins. In human U1 snRNP, seven different Sm subunits assemble around a segment of U1 small nuclear RNA. This core helps organize the particle that participates in RNA splicing.^[ref]

Seven subunits does not mean seven copies of one protein: the canonical ring contains B/B′, D1, D2, D3, E, F and G types. In a reconstituted U1-core experiment, heavy-atom labels associated with particular proteins identified their positions in an X-ray crystallography map. The assignment established an ordered arrangement of different subunits, beyond merely detecting their presence in one sample.^[ref]

For an original counting example, two complete canonical Sm rings contain14 subunits but only seven subunit types. Recovering14 protein molecules from a sample would not prove that two complete rings had assembled: the same count could include free components or incomplete particles. Composition, organization and RNA splicing activity consequently require different experimental evidence.

The Sm ring is also only part of the small nuclear ribonucleoprotein. Particle-specific proteins and the RNA contribute further interactions; the ring alone should not be equated with an intact spliceosome.

A splice donor site is the splice site at the $5^{\prime }$ end of an intron in a precursor RNA. It marks the boundary between the upstream exon and the intron. Its name is oriented along the precursor RNA, not along whichever direction a DNA reference sequence happens to be displayed.

In the toy precursor A|intron|B, with letters representing whole exons, the first boundary is the splice donor site and the second is the splice acceptor site. Removing the intron and joining A to B gives the mature splice junction. A change in donor choice can change the end of A even when acceptor choice remains fixed; this is one route to alternative splicing.

Recognition involves sequence and molecular context. The RNA component of U1 snRNP can base-pair with the donor region. A particularly informative experiment changed a donor sequence and then changed U1 to restore complementarity. Rescue of one donor mutation supported direct pairing; weak rescue of another showed that complementarity alone did not guarantee productive RNA splicing.^[ref]

This is a useful causal test: perturbing either partner can disrupt an interaction, while a compensating change in the other partner can distinguish a specific pairing model from a generic loss of function. A candidate sequence bound by U1 snRNP still has to participate in the rest of the spliceosome's reaction.

U1A protein is an RNA-binding protein component of U1 snRNP. Its N-terminal RNA recognition motif binds stem-loopII of U1 small nuclear RNA, helping distinguish a specific RNA-binding interaction from the assembly of the entire small nuclear ribonucleoprotein.^[ref]

A1994 X-ray crystallography study determined a complex of the U1A RNA-binding domain and an RNA hairpin at $1.92\mathring{\mathrm{A}}$ resolution. This was a domain–RNA complex, not a structure of a complete spliceosome.^[ref]

For an original one-site binding example, suppose a domain binds one RNA molecule with dissociation constant $K_d$ and free RNA concentration $[R]$. Under the stipulated equilibrium model, the bound fraction of domains isIf $K_d=10\mathrm{nM}$, then $[R]=10\mathrm{nM}$ gives $f=1/2$, whereas $[R]=90\mathrm{nM}$ gives $f=0.9$. These invented constants illustrate binding affinity; they are not measured U1A values and assume free, rather than total, RNA concentration.

Binding of an isolated domain does not by itself demonstrate functional RNA splicing. A later U1-core crystallographic study omitted U1A from its engineered particle and added a previously known U1A–RNA structure when modeling the complete assembly. Distinguishing observed components from modeled additions is essential to interpreting that experiment.^[ref]

U1 small nuclear RNA, or U1 snRNA, is the small nuclear RNA component of U1 snRNP. The RNA and the assembled ribonucleoprotein are distinct objects: the particle also contains proteins. U1's $5^{\prime }$ region recognizes many splice donor sites by complementary pairing during spliceosomal RNA splicing.^[ref]

A simple base-pair model illustrates a compensatory test. Suppose a donor base A pairs with a U in U1. Changing the donor A to C creates a C–U mismatch. Changing the corresponding U1 base to G restores a C–G pair. This is a hypothetical pair chosen to explain the experiment's logic, rather than the exact sequence of a published mutant.

In the original test, mutations at two alternative donor sites were paired with compensating changes in human U1. One mutation at donor position+5 was efficiently suppressed, whereas a different mutation at position+3 was only weakly suppressed. The unequal rescue supported direct pairing while showing that pairing alone was insufficient for productive splicing.^[ref]

The comparison distinguishes molecular recognition from the entire processing pathway. Restoring complementarity tests a particular RNA–RNA contact; it does not establish that every later event in spliceosome assembly and catalysis has also been restored. Similarly, the presence of U1 snRNA alone is not equivalent to assembling a complete active U1 snRNP.